info:eu-repo/semantics/article
Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies
Registro en:
Montoya A, Daza A, Muñoz D, Ríos K, Taylor V, Cedeño D, Vélez ID, Echeverri F, Robledo SM. Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies. Antimicrob Agents Chemother. 2015 Sep;59(9):5804-13. doi: 10.1128/AAC.00545-15.
0066-4804
10.1128/AAC.00545-15
1098-6596
Autor
Montoya Cuervo, Edwin Andrés
Daza Figueredo, Juan Alejandro
Muñoz Herrera, Diana Lorena
Ríos Ramírez, Yesmit Karina
Taylor Orozco, Viviana Milena
Cedeño, David
Vélez Bernal, Iván Darío
Echeverri López, Luis Fernando
Robledo Restrepo, Sara María
Institución
Resumen
ABSTRACT:An evaluation of the leishmanicidal activity in vitro and in vivo of hypericin, an expanded-spectrum photosensitizer found in Hypericum perforatum, is presented. Hypericin was evaluated against intracellular amastigotes in vitro of Leishmania (Viannia) panamensis. A topical formulation containing 0.5% hypericin was developed and assayed in vivo in a hamster model of cutaneous leishmaniasis. Results demonstrate that hypericin induces a significant antiamastigote effect in vitro against L. panamensis by decreasing the number of parasites inside infected cells. The topical formulation of 0.5% hypericin allows healing of L. pana-
mensis-induced lesions upon a topical application of 40 mg/day plus visible-light irradiation (5 J/cm2, 15 min), twice a week for 3 weeks. COL0015339 COL0015099